Annovis Bio Inc. (NYSE: ANVS) Plans Investor Webcast

Annovis Bio Inc., based in Malvern, Pennsylvania, has announced an upcoming investor webcast scheduled for June 11, 2024, at 4:30 pm ET. The webcast will focus on the latest developments and strategic plans for Buntanetap, the company's leading drug candidate aimed at treating neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD).

During the webcast, Annovis will present significant recent advancements in the development of Buntanetap, its strategic plans for future clinical trials, and an overview of the company's progress and future direction. Investors and interested parties are encouraged to register for the webcast in advance.

Buntanetap, formerly known as Posiphen or ANVS401, is a drug designed to combat neurodegeneration by inhibiting the formation of several neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. By enhancing synaptic transmission, improving axonal transport, and reducing neuroinflammation, Buntanetap aims to reverse the effects of neurodegeneration in diseases like AD and PD.

Annovis Bio Inc. is committed to addressing the challenges of neurodegenerative diseases through innovative therapeutic strategies. The company's approach focuses on targeting multiple neurotoxic proteins with the goal of restoring brain function and improving the quality of life for patients affected by these debilitating conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!